Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder

BJU International

Volumn 98, Issue 5, 2006, Pages 1012-1017

  Saxena, Sunita ^a   Agrawal, Usha ^a   Agarwal, Abhilasha ^a   Murthy, Nandagudi Srinivasa ^a   Mohanty, Nayan Kumar ^b  

^a SAFDARJUNG HOSPITAL CAMPUS   (India)

^b SAFDARJUNG HOSPITAL   (India)

Author keywords

Adjuvant immunotherapy; Chemotherapy; In vitro cytotoxicity; Individualized therapy; Intravesical therapy; Superficial TCC bladder

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; IMMUNOMODULATING AGENT; MITOMYCIN C;

ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTOSCOPY; DISEASE FREE SURVIVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; KAPLAN MEIER METHOD; MALE; PRIORITY JOURNAL; SUPERFICIAL CANCER; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 33749549703     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06482.x     Document Type: Article

References (30)

1. Landis SH, Murray T, Bolden S, Wingo PA, Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31
2. Lamm DL, Griffith JG. Intravesical therapy: does it affect the natural history of superficial bladder cancer. Semin Urol 1992; 10: 39-44
3. Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS eds, Comprehensive Textbook of Genitourinary Oncology. Philadelphia: Lippincott, Williams and Wilkins, 2000; 394-417
4. Borden E, Groveman D, Nasu T, Reznikoff C, Bryan GT. Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J Urol 1984; 132: 800-3
5. Lamm DL, Crawford ED, Blumenstein B et al. A randomized comparison of bacillus Calmette-Guerin and mitomycin-C prophylaxis in stage Ta and T1 transitional cell carcinoma of the bladder. Urol Oncol 1995; 1: 119-26
6. Martinez-Pineiro JA, Jimenez Leon J, Martinez-Pineiro L Jr et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 1990;143: 502-6
7. Masters JR, McDermott BJ, Harland S, Bibby MC, Loadman PM. ThioTEPA pharmacokinetics during intravesical chemotherapy: The influence of dose and volume of instillate on systemic uptake and dose rate to the tumor. Cancer Chemother Pharmacol 1996; 38: 59-64
8. Agiostratidou G, Sgouros I, Galani E et al. Correlation of in vitro cytotoxicity and clinical response to chemotherapy in ovarian and breast cancer patients. Anticancer Res 2001; 21: 455-9
9. Hisazumi H, Uchibayashi T, Katoh M et al. Anticancer drug sensitivity in vitro in the bladder cancer cell line, KK-47 and prophylactic use of carbazilquinone and urokinase in bladder cancer. Urol Res 1981; 9: 231-5
10. Epstein JI, Amin MB, Reuter UR, Mostofi FK. The World Health Organization/International Society of Urological Pathology Consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 1435-48
11. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124-9
12. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumours. J Urol 1976; 116: 180-3
13. Morales A, Nickel C, Wilson JW. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol 1992; 147: 1256-8
14. Pagano F, Bassi P, Milani C et al. Low dose BCG-Pasteur strain in the treatment of superficial bladder cancer: preliminary results. In DeBruyne FM, Denis L, van der Meijden AP eds, BCG in Superficial Bladder Cancer, EORTC Genitourinary Group, Monograph 6. New York: Alan R Liss, 1989: 253-7
15. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999; 353: 1689-94
16. Böhle A. Recent knowledge on BCG's mechanism of action in the treatment of superficial bladder cancer. Braz J Urol 2000; 26: 488-502
17. Jansson OT, Morcos E, Brundin L et al. The role of nitric oxide in bacillus Calmette-Guerin mediated anti-tumour effects in human bladder cancer. Br J Cancer 1998; 78: 588-92
18. Berry DL, Blumenstein BA, Magyary DL, Lamm DL, Crawford ED. Local toxicity patterns associated with intravesical bacillus Calmette-Guerin: a Southwest Oncology Group Study. Int J Urol 1996; 3: 98-101
19. Bouffioux C, Denis L, Oosterlinck W et al. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of an European Organisation for Research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group J Urol 1992; 148: 297-301
20. Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organisation for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 149: 749-52
21. van der Meijden AP, Kurth KH, Oosterlinck W, DeBruyne FM. Intravesical therapy with Adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU group. Cancer Chemother Pharmacol 1992; 30 (Suppl.): S95-8
22. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-α2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 2001; 166: 1300-5
23. Glashan RW. A randomized controlled study of intravesical α-2b-interferon in carcinoma in situ of the bladder. J Urol 1990; 144: 658-61
24. O'Donnell MA. Combined bacillus Calmette-Guerin and interferon use in superficial bladder cancer. Expert Rev Anticancer Ther 2003; 3: 809-21
25. Ratliff TL, Kavoussi LR, Catalona WJ. Role of fibronectin in intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 1988; 139: 410-4
26. Jeong CW, Jeon HG, Kwak C, Jeong H, Lee SE. Comparison of 30mg and 40mg of mitomycin C intravesical instillation in Korean superficial bladder cancer patients: a prospective randomized study. Cancer Res Treat 2005; 37: 44-7
27. Masters JR, Popert RJ, Thompson PM, Gibson D, Copecoat MJ, Parmar MK. Intravesical chemotherapy with epirubicin: a dose-response study. J Urol 1999; 161: 1490-3
28. Au JL, Badalament RA, Wientjes MG et al.; International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001; 93: 597-604
29. Chen LK, Tourvieille B, Burns GF et al. Interferon: a cytotoxic T lymphocyte differentiation signal. Eur J Immunol 1986; 16: 767-70
30. Pellegrini P, Berghella AM, Del Beato T, Cicia S, Adorno D, Casciani CU. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 1996; 42: 1-8